Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study.
Rimini M, Shimose S, Lonardi S, Tada T, Masi G, Iwamoto H, Lai E, Burgio V, Hiraoka A, Ishikawa T, Soldà C, Shirono T, Vivaldi C, Takaguchi K, Shimada N, Astara G, Koga H, Nouso K, Joko K, Torimura T, Hiasa Y, Salani F, Scartozzi M, Cascinu S, Casadei-Gardini A.
Rimini M, et al. Among authors: koga h.
Hepatol Res. 2021 Dec;51(12):1229-1241. doi: 10.1111/hepr.13718. Epub 2021 Oct 21.
Hepatol Res. 2021.
PMID: 34591334